Gracell Biotechnologies Inc. (GRCL) Analyst Estimates Annual - Discounting Cash Flows
GRCL
Gracell Biotechnologies Inc.
GRCL (NASDAQ)
Period Ending: 2025
12-31
2024
12-31
2023
12-31
2022
12-31
2021
12-31
Number of Analysts 0 0 0 0 0
Estimated Revenue
Low 1.04 0 0 0.141 0.412
Average 0.92 0 0 0.125 0.366
High 0.74 0 0 0.101 0.294
Estimated EBITDA
Low 0.621 0 0 0.084 0.247
Average 0.552 0 0 0.075 0.22
High 0.444 0 0 0.06 0.177
Estimated EBIT
Low 0.621 0 0 0.084 0.247
Average 0.552 0 0 0.075 0.22
High 0.444 0 0 0.06 0.177
Estimated Net Income
Low -66.19 -155.9 -134.4 -84.53 -12.43
Average -57.24 -132.2 -125.8 -73.09 -10.75
High -43.22 -102.1 -112.9 -55.19 -8.12
Estimated SGA Expenses
Low None None None None None
Average None None None None None
High None None None None None
Estimated EPS
Low -0.616 -1.45 -1.25 -0.786 -0.116
Average -0.532 -1.23 -1.17 -0.68 -0.1
High -0.402 -0.95 -1.05 -0.513 -0.076
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program